61 / 84
LVivo SG
LVivo EF
with the conventional evaluation
method, which use manually-selected
still images as the basis for calculation.
The ease and speed of DiACardio’s
tools also make it practical to carry out
short-cycle, repeatable measurements
of patients associated with the risk of
the cardiotoxicity effect that may be
caused by chemotherapy. DiAcardio’s
tools are able to analyze patient data
online within the echo unit and/or
offline on the PACS’s DICOM video
file, taking into account the dynamic
nature of the heart. DiAcardio
technologies are protected by patents
(currently at the national phase).
Road map
Our target customers are Ultrasound
manufacturers, Healthcare IT (PACS)
companies and other medical imaging
software companies. We sell our
software tools on an OEM basis as an
integrated plug-in solution.
R&D Road map -During 2016 we
intend to finish the development of
additional 4 cardiac automated tools,
obtain FDA/CE for LVivo SG and
publish academic articles.
M&S road map– we intend to increase
dramatically the marketing and sales
of LVivo platform and detect potential
partners for our current and upcoming
tools.
Financial round map - until the end
of the first half of 2016 we intend
to close an A Round of investment
of $5M-$10M that will allows us
to expend our technology to other
medical imaging platforms and
application
Awards
DiaCardio won 1st place at the ICI
innovation awards, just few months
after winning 1st place at GIA2015
in China. DiACardio, a Software
company, revolutionizes the practice
of evaluating “Ultrasound of the
heart” (“Echocardiography”), by
evaluating the heart performance
automatically, at the click of a mouse,
in just a few seconds. DiaCardio’s
software can easily integrated into
any ultrasound unit and healthcare
IT (PACS) system. The software is
FDA cleared and CE approved and
initial sales have been obtained. Co-
founders, Hila Goldman-Aslan, the
company’s CEO and Co-Founder and
Dr. Noah Liel-Cohen M.D., Head of
the Echocardiography Unit at Soroka
University Medical Center in Beer-
Sheva , presented DiaCardio. The ICI
is a global innovation in cardiology
conference held for the 20th time.
This time a specific focus was on
revolution of digital/mobile health
technologies. Each year more than 70
applications from 22 countries around
the world send their application. Only
10 selected companies are invited to
present. DiACardio was evaluated by
expert panel judges based of 3principal
criteria: the impact on patient care,
the impact on novelty and business
potential. “Winning this awards is
a recognition from the cardiology
community of our ground-breaking
technology that we have developed at
DiACardio” said Hila Goldman-Aslan,
the company’s CEO and Co-Founder.
Part of wining, DiACardio also gets the
chance to present at Europe’s largest
cardiovascular conference - EuroPCR
2016 (Paris).
61 l New-Tech Magazine Europe